Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

[1]  H. Joensuu,et al.  Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. , 2015, European journal of cancer.

[2]  J. Blay,et al.  Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. , 2015, The oncologist.

[3]  M. Schuler,et al.  Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST). , 2015 .

[4]  J. Jónasson,et al.  KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Blay,et al.  Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST , 2014, Clinical Cancer Research.

[6]  C. Raut,et al.  Surgical management of localized soft tissue tumors , 2014, Cancer.

[7]  H. Cao,et al.  Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. , 2014, European journal of cancer.

[8]  C. Antonescu,et al.  Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Nancy L Keating,et al.  A systematic assessment of benefits and risks to guide breast cancer screening decisions. , 2014, JAMA.

[10]  Aki Vehtari,et al.  Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. , 2014, Radiology.

[11]  F. van Coevorden,et al.  Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  C. Raut,et al.  Treatment of localized sarcomas. , 2013, Hematology/oncology clinics of North America.

[13]  M. Leahy,et al.  Patterns of recurrence of gastrointestinal stromal tumour (GIST) following complete resection: implications for follow-up. , 2013, Clinical radiology.

[14]  D. Niederwieser,et al.  Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA , 2013, Clinical Cancer Research.

[15]  J. Blay,et al.  Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. , 2013 .

[16]  G. Whalen,et al.  Rational follow-up after curative cancer resection. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[18]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[19]  G. Gatta,et al.  Rare cancers are not so rare: the rare cancer burden in Europe. , 2011, European journal of cancer.

[20]  J. Izbicki,et al.  Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. , 2011, The Journal of surgical research.

[21]  The risks of radiation exposure related to diagnostic imaging and how to minimise them , 2011, BMJ : British Medical Journal.

[22]  F. Gleeson,et al.  The risks of radiation exposure related to diagnostic imaging and how to minimise them , 2011, BMJ : British Medical Journal.

[23]  J. Carles,et al.  Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  C. Mussi,et al.  Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Joensuu.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[26]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Desai,et al.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[29]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.

[30]  E. Wardelmann,et al.  Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.

[31]  M. van Glabbeke,et al.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[33]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[34]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[35]  A. Depierre,et al.  Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. , 2000, The Annals of thoracic surgery.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  P. G. Casali,et al.  Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  D.,et al.  Regression Models and Life-Tables , 2022 .